Dr. Michael E Sandlin, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 1201 S Belmont Ave, Ste 207, Okmulgee, OK 74447 Phone: 918-758-0555 Fax: 918-758-3431 |
News Archive
ARIAD Pharmaceuticals, Inc. today announced that following a priority review, the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.
Jim Ely tackles life like Mean Joe Greene tackled running backs. A banker, he also worked weekends as a football referee for 38 years and still, at age 83, works as home-game timekeeper for the Dallas Cowboys.
Morphotek, Inc., a subsidiary of Eisai Inc., today announced that a monoclonal antibody has been selected for advancement to clinical development under the terms of its March 2009 collaboration agreement with Human Genome Sciences, Inc.
Almost Family, Inc., a leading regional provider of home health nursing services, announced today it has entered into a new five-year $125 million revolving credit facility that increases its financial flexibility through 2015 (the Facility). J.P. Morgan Securities LLC acted as sole bookrunner and sole lead arranger, while Bank of America, N.A. acted as syndication agent under the Facility which replaced the Company's previous $75 million credit facility.
GeoVax Labs, Inc., announced today the expansion of the Phase 2a clinical trial testing of its HIV/AIDS vaccine products. The expanded Phase 2a trial will test the administration of three doses of the recombinant poxvirus vaccine MVA62B without the use of the recombinant DNA-vectored vaccine, which was used to prime immune responses in the first part of this trial.
› Verified 7 days ago